0001493152-24-020673.txt : 20240520 0001493152-24-020673.hdr.sgml : 20240520 20240520160521 ACCESSION NUMBER: 0001493152-24-020673 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240520 ITEM INFORMATION: Other Events FILED AS OF DATE: 20240520 DATE AS OF CHANGE: 20240520 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TC BioPharm (Holdings) plc CENTRAL INDEX KEY: 0001872812 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41231 FILM NUMBER: 24964385 BUSINESS ADDRESS: STREET 1: MAXIM 1 STREET 2: 2 PARKLANDS WAY CITY: HOLYTOWN STATE: X0 ZIP: ML1 4WR BUSINESS PHONE: 01414337557 MAIL ADDRESS: STREET 1: MAXIM 1 STREET 2: 2 PARKLANDS WAY CITY: HOLYTOWN STATE: X0 ZIP: ML1 4WR FORMER COMPANY: FORMER CONFORMED NAME: TC BioPharm (Holdings) Ltd DATE OF NAME CHANGE: 20210721 FORMER COMPANY: FORMER CONFORMED NAME: TC BioPharm Ltd DATE OF NAME CHANGE: 20210714 8-K 1 form8-k.htm
false 0001872812 0001872812 2024-05-20 2024-05-20 0001872812 TCBP:AmericanDepositarySharesEachRepresentingMember 2024-05-20 2024-05-20 0001872812 TCBP:OrdinarySharesNominalValue0.0001PerShareMember 2024-05-20 2024-05-20 0001872812 TCBP:WarrantsMember 2024-05-20 2024-05-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 20, 2024

 

TC Biopharm (Holdings) PLC

(Exact name of registrant as specified in charter)

 

Scotland   001-41231   N/A
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)  

Identification No.)

 

Maxim 1, 2 Parklands Way, Holytown, Motherwell,

Scotland, United Kingdom

   ML1 4WR
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: +44 (0) 141 433 7557

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
American Depositary Shares, each representing
twenty Ordinary Shares, nominal value £0.0001 per share		   TCBP   The Nasdaq Stock Market LLC
Ordinary Shares, nominal value £0.0001 per share*   N/A   The Nasdaq Stock Market LLC
Warrants   TCBPW   The Nasdaq Stock Market LLC

 

* Not for trading, but only in connection with the listing of the American Depositary Shares on The NASDAQ Stock Market LLC.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 8.01. Other Events.

 

On May 15, 2024, TC Biopharm (Holdings) PLC (the “Company”) filed its Form 10-Q for the quarter ended March 31, 2024 (the “Form 10-Q”). As noted in the Form 10-Q, the Company was not in compliance with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on The Nasdaq Capital Market because its stockholders’ equity was below the required minimum of $2.5 million at March 31, 2024 (the “Minimum Stockholders’ Equity Requirement”).

 

As previously reported in our Current Report on Form 8-K filed with the Securities and Exchange Commission on May 8, 2024, on May 6, 2024, the Company entered into a letter agreement (the “Inducement Letter”) with certain holders (the “Holders”) of existing Series E warrants (the “Existing Warrants”) to purchase ordinary shares represented by american depositary shares (the “ADSs”) of the Company. Pursuant to the Inducement Letter, the Holders agreed to exercise for cash their Existing Warrants to purchase an aggregate of 1,750,000 ADSs of the Company for cash and the payment of £0.099625 (US$0.125) per new warrant in consideration for the Company’s agreement to issue new Series F warrants to purchase ordinary shares represented by ADSs (the “New Warrants”) to purchase up to 70,000,000 of the Company’s ordinary shares represented by 3,500,000 ADSs (the “New Warrant ADSs”). On May 8, 2024, the Company received aggregate gross proceeds of approximately £3.1 million (circa $3.9m) from the exercise of the Existing Warrants by the Holders, prior to deducting placement agent fees and estimated offering expenses.

 

The Company believes that due to the exercise of the Existing Warrants it is now in compliance with the Minimum Stockholders’ Equity Requirement as of the date of the filing of this Form 8-K.

 

-2-
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 20, 2024  
  TC BIOPHARM (HOLDINGS) PLC
   
  By: /s/ Martin Thorp
    Martin Thorp
    Chief Financial Officer

 

-3-

 

 EX-101.SCH 2 tcbp-20240520.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 tcbp-20240520_def.xml XBRL DEFINITION FILE EX-101.LAB 4 tcbp-20240520_lab.xml XBRL LABEL FILE Class of Stock [Axis] American Depositary Shares, each representing Ordinary Shares, nominal value £0.0001 per share* Warrants Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 tcbp-20240520_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
May 20, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date May 20, 2024
Entity File Number 001-41231
Entity Registrant Name TC Biopharm (Holdings) PLC
Entity Central Index Key 0001872812
Entity Address, Address Line One Maxim 1
Entity Address, Address Line Two 2 Parklands Way
Entity Address, Address Line Three Holytown
Entity Address, City or Town Motherwell
Entity Address, Country GB
Entity Address, Postal Zip Code ML1 4WR
City Area Code +44 (0) 141
Local Phone Number 433 7557
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
American Depositary Shares, each representing  
Title of 12(b) Security American Depositary Shares, each representing
Trading Symbol TCBP
Security Exchange Name NASDAQ
Ordinary Shares, nominal value £0.0001 per share*  
Title of 12(b) Security Ordinary Shares, nominal value £0.0001 per share*
Trading Symbol N/A
Security Exchange Name NASDAQ
Warrants  
Title of 12(b) Security Warrants
Trading Symbol TCBPW
Security Exchange Name NASDAQ
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 4 23 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://tcbiopharm.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [dq-60547-EntityIncorporationStateCountryCode-Missing] Submission type 8-K should have a non-empty value for EntityIncorporationStateCountryCode in the Required Context. form8-k.htm [dq-60547-EntityTaxIdentificationNumber-Missing] Submission type 8-K should have a non-empty value for EntityTaxIdentificationNumber in the Required Context. form8-k.htm form8-k.htm tcbp-20240520.xsd tcbp-20240520_def.xml tcbp-20240520_lab.xml tcbp-20240520_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "TCBP", "nsuri": "http://tcbiopharm.com/20240520", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "tcbp-20240520.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "definitionLink": { "local": [ "tcbp-20240520_def.xml" ] }, "labelLink": { "local": [ "tcbp-20240520_lab.xml" ] }, "presentationLink": { "local": [ "tcbp-20240520_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 3, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 4, "entityCount": 1, "segmentCount": 3, "elementCount": 66, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 29 }, "report": { "R1": { "role": "http://tcbiopharm.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "TCBP_AmericanDepositarySharesEachRepresentingMember": { "xbrltype": "domainItemType", "nsuri": "http://tcbiopharm.com/20240520", "localname": "AmericanDepositarySharesEachRepresentingMember", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "American Depositary Shares, each representing" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "TCBP_OrdinarySharesNominalValue0.0001PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://tcbiopharm.com/20240520", "localname": "OrdinarySharesNominalValue0.0001PerShareMember", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Ordinary Shares, nominal value \u00a30.0001 per share*" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "TCBP_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://tcbiopharm.com/20240520", "localname": "WarrantsMember", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Warrants" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://tcbiopharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001493152-24-020673-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-020673-xbrl.zip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end XML 18 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001872812 2024-05-20 2024-05-20 0001872812 TCBP:AmericanDepositarySharesEachRepresentingMember 2024-05-20 2024-05-20 0001872812 TCBP:OrdinarySharesNominalValue0.0001PerShareMember 2024-05-20 2024-05-20 0001872812 TCBP:WarrantsMember 2024-05-20 2024-05-20 iso4217:USD shares iso4217:USD shares false 0001872812 8-K 2024-05-20 TC Biopharm (Holdings) PLC 001-41231 Maxim 1 2 Parklands Way Holytown Motherwell GB ML1 4WR +44 (0) 141 433 7557 false false false false American Depositary Shares, each representing TCBP NASDAQ Ordinary Shares, nominal value £0.0001 per share* N/A NASDAQ Warrants TCBPW NASDAQ true false